Abstract
Figures and Tables
Fig. 1
![jkd-13-172-g001](/upload/SynapseData/ArticleImage/0178jkd/jkd-13-172-g001.jpg)
Fig. 2
![jkd-13-172-g002](/upload/SynapseData/ArticleImage/0178jkd/jkd-13-172-g002.jpg)
Fig. 3
![jkd-13-172-g003](/upload/SynapseData/ArticleImage/0178jkd/jkd-13-172-g003.jpg)
Table 1
![jkd-13-172-i001](/upload/SynapseData/ArticleImage/0178jkd/jkd-13-172-i001.jpg)
aLimited use in the U.S./Europe. bNotlicensed in the U.S. cPrescribing highly restricted in the U.S.;with drawn in Europe. dNotlicensed in Europe. eTo be available as a generic product in 2012, with expected significant reductions in cost. fDepends on type (analogs > human insulins) and dosage;CKD,chronickidneydisease;CVD, cardiovascular disease;DPP-4, dipeptidyl peptidase 4;GIP, glucose-dependent insulinotropic peptide; GLP-1, glucagon-like peptide1;HDL-C, HDL-cholesterol;LDL-C, LDL-cholesterol;PPAR, peroxisome proliferator-activated receptor;ProACTIVE, ProspectivePioglitazone Clinical Trialin Macrovascular Events(60); STOP-NIDDM, Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (134);UKPDS, UK Prospective DiabetesStudy (29-33).
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)